AzTrials
AzTrials

Postpartum Haemorrhage With Retained PlacentaPhase 2NCT03395730

Intraumbilical Oxytocin Versus Placental Cord Drainage in the Management of 3rd Stage of Labor

A Phase 2 study testing Intraumbilical vein injection oxytocin, placental cord drainage and Expectant managment of 3rd stage of labour in people with Postpartum Haemorrhage With Retained Placenta, run by Eslam Mohammed Abbas at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this study is to compare the effectiveness of intraumbilical oxytocin and placental cord drainage in the management of third stage of labor. Does the use of intraumbilical vein oxytocin injection or the use of Placental cord drainage can cause a reduction of blood loss, Hb level drop, the length of the… Read more about this study

Who is it for?
Ages 18 to 35 years, women onlyHealthy volunteers can take part
What is being tested?
Intraumbilical vein injection oxytocin, placental cord drainage and Expectant managment of 3rd stage of labour
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150 participants
Where
1 siteEgypt
Study dates
30 Sep 2017to 30 Jan 2018
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Pregnant women between 18-35 years of age with normal pregnancy.
  • A singleton fetus at a gestational age of 37 - 42 weeks in a cephalic presentation.
  • Neonatal birth weight of 2500 to 4500 grams.

Who cannot join

  • Medical disorders and hypertensive disorders of pregnancy.
  • Intrauterine fetal death.
  • Known or suspected fetal anomalies.
  • Oxytocin induction or augmented cases.
  • Obstetrical complications (bleeding, premature rupture of membranes).
  • Previous CS or Previous Myomectomy.

Trial locations and contacts

1 site in 1 country.

Islam M Abbas, MBBch contact

00201025864906

dr.eslamabbas@gmail.com

Egypt1 site, 1 recruiting
  • Ain Shams Maternity Hospital

    Cairo, 11311

    Tamer F Borg, PHD, 00201001457437, tamerborg1975@gmail.com

    Bassem A Islam, PHD, 00201002412634, aly.bassem74@gmail.com

    Recruiting

Other trials in Egypt

About this study

Official title: Intraumbilical Oxytocin Compared to Placental Cord Drainage in the Management of Third Stage of Labor: A Randomized Controlled Study

The aim of this study is to compare the effectiveness of intraumbilical oxytocin and placental cord drainage in the management of third stage of labor.

Does the use of intraumbilical vein oxytocin injection or the use of Placental cord drainage can cause a reduction of blood loss, Hb level drop, the length of the third stage of labor and the incidence of manual removal of the retained placenta during the third stage of labor in pregnant women after delivery of the infant?

Read the detailed description

Study:

Study Design: A prospective randomized clinical trial. Study setting: The study will be conducted in Ain Shams University Maternity Hospital.

All pregnant women in the delivery ward will be submitted to:

  1. Detailed complete history taking with special emphasis to maternal age, Parity, Maternal weight, as well as presence of any disease.
  2. Clinical Examination:
  3. General examination. b. Abdominal examination (Symphysis-fundal height) and pelvic examination.
  4. Investigation
  5. Ultrasound assessment to evaluate GA, fetal weight, AFI and Placental site.
  6. Basal complete blood picture, urine analysis and random blood sugar. The selected patients will fulfill the following criteria:
  • Pregnant women between 18-35 years of age with normal pregnancy.
  • A singleton fetus at a gestational age of 37 - 42 weeks in a cephalic presentation.
  • Neonatal birth weight of 2500 to 4500 grams. Exclusion criteria:
  • Medical disorders and hypertensive disorders of pregnancy.
  • Intrauterine fetal death.
  • Known or suspected fetal anomalies.
  • Oxytocin induction or Augmented cases.
  • Obstetrical complications (bleeding, premature rupture of membranes).
  • Previous CS or Previous Myomectomy. Study population: The present study will be conducted on 150 women recruited from the delivery ward of our hospital after they had received information on the purpose and course of the study from the medical investigator and had provided the written consent during routine prenatal visits , The 150 study participants will be divided into three groups using simple random distribution technique. After monitoring the duration of active phase and second stage of labor by following the partograph. Randomization and Allocation concealment: Randomization will be based on the sequence generation created by computer and the randomization tables will be kept with the study supervisor. Consenting patients fulfilling inclusion criteria will be randomized into one of the following 3 groups. Randomized allocation will be kept in opaque sealed envelopes, with enrollment numbers written on the envelopes. The envelopes will contain a card on with the designated study group will be written. After enrollment of the patients in the study, the envelopes marked with study number will be unsealed and the patients allocated to either groups:
  • Group (A) "Study Group 1": In the labor room women in Group A (n = 50) receive intraumbilical vein injection oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
  • Group (B) "Study Group 2": The women in Group B (n = 50) have placental drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
  • Group (C) "Control Group": The women in Group C (n = 50) as a control group receive no intervention. Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby. Outcome: Retained placenta is defined as a placenta that remained in the uterus for 30 minutes or more after delivery (Begley et al., 2014).
  • 1ry outcome: Duration of the third stage of labor.
  • 2ry outcome: Retained placenta, need for manual removal of placenta and the drop in Hb will be recorded. Sample size calculation: Sample size was calculated using PASS® version 11 program, sample size calculation was based on study carried out by (Güngördük et al., 2011). A preliminary power analysis was carried out to calculate the sample size using a formula: d = Δ/SD, where d is standardized difference, Δ is the smallest clinically significant difference and SD is standard deviation of the test group. Duration of 1.6 minutes was considered as the smallest clinically significant difference, and the SD (1.6 minutes) was selected the study performed by (Güngördük et al., 2011). Also, a standardized difference of 1.0 was obtained using nomogram. The power analysis suggested that a sample of 50 women in each group would provide a power of 95%, at 5% significance.
Being tested
Intraumbilical vein injection oxytocin, placental cord drainage, Expectant managment of 3rd stage of labour

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intraumbilical vein injection oxytocinDrug

    intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.

  • placental cord drainageProcedure or surgery

    placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.

  • Expectant managment of 3rd stage of labourProcedure or surgery

    Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.

Study groups in NCT03395730
Study groupRoleWhat they receive
• Group (A) "Study Group 1":ExperimentalIn the labor room women in Group A (n = 50): * Clamping and cutting the placental cord after delivery of the baby. * Immediate intraumbilical vein injection of Oxytocin (Syntocinon®) 20 units diluted in 20 ml of 0.9% saline solution
Receives: Drug: Intraumbilical vein injection oxytocin
• Group (B) "Study Group 2":ExperimentalIn the labor room women in Group B (n = 50): * Clamping and cutting the placental cord after delivery of the baby. * Immediate unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
Receives: Procedure: placental cord drainage
• Group (C) "Control Group":Active comparatorIn the labor room women in Group C (n = 50): * Clamping and cutting the placental cord after 2 minutes of delivery of the baby. * Placenta will be delivered spontaneously after appearance of clinical signs of placental separation
Receives: Procedure: Expectant managment of 3rd stage of labour

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Duration of the third stage of labor.

    Duration of placental expulsion from the uterus after delivery of the fetus. by the use of a stop watch to calculate the time in minutes and seconds passing starting from the delivery of the baby till delivery of the placenta outside the the vagina.

    To compare How long does the 3rd stage of labor persist with each intervention (in minutes and seconds).

    Measured: 5-15 minutes

Secondary outcomes (3)
  1. Retained placenta

    defined as a placenta that remained in the uterus for 30 minutes or more after delivery.

    by the use of a stop watch to calculate the time in minutes and seconds needed for placental expulsion.

    To compare which intervention can result in delayed expulsion of placenta (in minutes and seconds) and cause a retained placenta.

    Measured: >30 minutes

  2. the Need for manual removal of placenta

    manual removal of the placenta under general anesthesia if the placental expulsion is delayed for more than 30 minutes.

    to compare which intervention will require manual removal of the retained(by the percentage of yes and no) placenta.

    Measured: > 30 minutes

  3. the drop in hemoglobin in gm/dl

    hemoglobin concentration in gm/dl will be measured for all participants before onset of delivery of the baby and 2 hours after labour and compare which maneuver included increased blood loss determined by the difference of hemoglobin concentration in gm/dl in the basal Hb level and the 2hr later Hb level.

    Measured: after 2 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jan 2018
  2. Study start30 Sep 2017
  3. Primary completion15 Jan 2018 (estimated)
  4. Study completion30 Jan 2018 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
The present study will be conducted on 150 women recruited from the delivery ward of our hospital after they had received information on the purpose and course of the study from the medical investigator and had provided the written consent during routine prenatal visits , they will be randomly divided into: * Group (A) "Study Group 1": (n = 50) * Group (B) "Study Group 2": (n = 50) * Group (C) "Control Group": (n = 50)
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03395730
Sponsor's protocol ID
ppsi
Status last verified
Jan 2018
First submitted
28 Dec 2017
Last updated
10 Jan 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Intraumbilical vein injection oxytocin, placental cord drainage and Expectant managment of 3rd stage of labour in people with Postpartum Haemorrhage With Retained Placenta, run by Eslam Mohammed Abbas at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Islam M Abbas, MBBch (00201025864906, dr.eslamabbas@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Duration of the third stage of labor. (time frame: 5-15 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in